Asia Pacific Preventive Vaccines Market to Generate Revenue of US$ 55.8 Billion By 2031 | Astute Analytica

Asia Pacific Preventive Vaccines Market size was US$ 19.8 billion in 2022 and is projected to surpass the market valuation of US$ 55.8 billion by 2031, growing at a CAGR of 7.22% during the forecast period from 2023 to 2031.

The Asia-Pacific region is at the forefront of global R&D spending, boasting the largest share in this field. Moreover, it holds significant shares in publications and patents related to preventive vaccine research and development. This region has earned a well-deserved reputation as a thriving hotspot for the preventive vaccines market, with numerous countries intensifying their efforts to safeguard healthcare and expand their industrial capabilities.

A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/asia-pacific-preventive-vaccines-market

The escalating demand for vaccines, coupled with robust government support for vaccine development, has propelled market growth in the region. Furthermore, the region’s unwavering commitment to embracing technological advancements has played a pivotal role in driving this expansion. As a result, the Asia-Pacific region continues to solidify its dominance in the field of preventive vaccines market.

With a population that accounts for over 60% of the global total, the Asia-Pacific region exhibits an undeniable demand for vaccines. This is evident from the substantial vaccine orders placed by various countries in the region in 2022. For instance, Vietnam procured 150 million doses, Thailand secured 90 million doses, and the Philippines obtained 85 million doses, all in an effort to strengthen their national vaccination campaigns.

However, effectively managing such a significant demand requires an efficient and robust supply chain. Recognizing this need, Malaysia has recently unveiled its impressive USS $500 million ‘Vaccine Logistics Hub’, which aims to not only streamline vaccine distribution within the country but also across the ASEAN region. This initiative demonstrates the region’s commitment to ensuring smooth and timely access to vaccines. These factors, including the enormous population, the substantial vaccine orders, and the establishment of strategic logistics hubs, contribute to the dominance of the preventive vaccines market in the Asia Pacific region.

The rapid pace of urbanization in the Asia Pacific region has had a profound impact on the preventive vaccines market, serving as a compelling catalyst for improved accessibility and distribution. The surge in urban growth, characterized by substantial migrations of people from rural to urban areas, has created an immediate requirement for effective healthcare infrastructure, including robust vaccine programs, to cater to the needs of the ever-expanding urban population.

In the past decade, Asia has witnessed a remarkable surge in urbanization, with over 200 million individuals flocking to its cities. The likes of Delhi, Shanghai, and Jakarta have become magnets for people seeking opportunities and a better life. This rapid urban growth has been nothing short of explosive, with staggering numbers like 8 million new urban residents in Beijing alone between 2010 and 2020.

However, this urban influx comes with its set of challenges, particularly in terms of public health. As cities become increasingly crowded, the risk of contagious diseases spreading like wildfire becomes a pressing concern. The dense population pockets that emerge in urban areas can serve as breeding grounds for these diseases, making it crucial to address the healthcare imperative intertwined with urbanization. As a result, this increases the need for the preventive vaccines market.

Technology Adoption: Making Easy the Production of Vaccines

The fusion of technology and healthcare in the Asia Pacific region has brought about a significant shift in the preventive vaccines market. This shift is characterized by the emergence of digital platforms that enhance the distribution and tracking of vaccines. Utilizing digital tools has become a crucial approach, enabling the efficient spread of vaccines, particularly as technology-savvy populations increasingly seek transparency and convenience in the vaccination process.

The demand for swift vaccine production, particularly in the midst of the COVID-19 pandemic, has necessitated the adoption of adaptable technologies. These technologies allow for the rapid adjustment and expansion of vaccine production processes to meet the increasing demand. The shift towards flexible technologies has played a crucial role in expediting the development and manufacturing of COVID-19 vaccines.

mRNA Vaccines Accounted for About 45% of Market Revenue Share

Messenger RNA (mRNA) vaccines dominate the vaccine types segment of the preventive vaccines market in the Asia Pacific region, holding a significant market share of 45.9% in 2022. It is anticipated that this market share will experience a slight increase, reaching 46.6% by the year 2031.

According to a recent study funded by Merck, a prominent science and technology company, mRNA technology is poised to revolutionize the landscape for vaccine manufacturers in the Asia-Pacific (APAC) region. These manufacturers are eagerly seeking to expand their capabilities in mRNA technology within the next two to three years, while also maintaining their production of conventional and cutting-edge cell-based vaccines. This shift marks a significant turning point in the industry, as APAC prepares to embrace the immense potential of mRNA vaccines alongside their existing repertoire.

Japan, South Korea, Australia, Indonesia, Singapore, China, and India are at the forefront of markets actively pursuing the development of mRNA technology. These countries have recognized the immense potential of mRNA vaccines and are taking proactive steps to explore and invest in this innovative field. In fact, over sixty percent of vaccine manufacturers in these markets are prioritizing the revamping or establishment of new facilities specifically dedicated to mRNA production. These manufacturers have ambitious expansion plans within the next two to three years, reflecting their commitment to harnessing the power of mRNA technology in the fight against infectious diseases.

The rapid rise of mRNA vaccines can be attributed to several significant factors. One key factor is the remarkable speed at which these vaccines were developed during the COVID-19 pandemic, showcasing their potential and effectiveness. Unlike traditional vaccine development methods, mRNA vaccines utilize genetic instructions to stimulate cells into producing a protein that triggers an immune response. This mechanism offers a faster and more streamlined approach to vaccine formulation, contributing to their accelerated development and widespread adoption.

Pediatric Patient Group Generated More Than 50% of Market Revenue Share

The pediatric sector is expected to dominate the market with an impressive share of over 56% by 2031, showing a significant increase from 55% in 2022. This surge underscores the heightened attention given to child health in the region, as well as the commitment to protecting the younger population from avoidable diseases.

Governments throughout the Asia Pacific region is well aware of the urgency surrounding this matter. Their determination to reduce healthcare expenses has led to the implementation of strong initiatives focused on expanding child immunization. Notably, programs such as the Vaccines for Children Program play a crucial role in this endeavor.

The Centers for Medicare and Medicaid Services (CMS) and the Centers for Disease Control (CDC) play a crucial role in this context. Their support and funding initiatives, including the endorsement of Moderna’s COVID-19 vaccine for children aged 6 to 17 in 2022, strengthen the market’s direction and progress. These institutions’ involvement and recommendations have a significant impact on shaping the trajectory of the market.

For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/asia-pacific-preventive-vaccines-market

China: The Front Runner Accounted for 47% of Market Revenue Share

China has emerged as the frontrunner in the Asia Pacific preventive vaccines market, capturing an impressive 47.2% market share in 2022. This dominance is expected to continue growing, reaching 47.8% by 2031. This remarkable achievement is a testament to China’s unwavering commitment to preventive healthcare, which is bolstered by its vast population and strategic healthcare initiatives.

As the world’s most populous country, China has a significant demand for vaccines. The country has implemented expansive immunization programs and is determined to achieve universal vaccination. These efforts have solidified China’s position as a key player in the market. Additionally, China’s focus on developing, producing, and distributing indigenous vaccines cannot be overlooked. This approach ensures that the nation has control over its vaccine supply and reduces its reliance on external sources.

China’s responsiveness in times of health emergencies is another factor that accentuates its dominance in the preventive vaccines market. The rapid development and deployment of COVID-19 vaccines exemplify the country’s ability to swiftly respond to critical health crises. This agility has not only protected its own population but has also earned China global recognition for its scientific advancements.

Top Players in the Asia Pacific Preventive Vaccines Market 

• Bharat Biotech
• CanSino Biologics
• Emergent BioSolutions Inc.
• GlaxoSmithKline PLC
• Novavax Inc.
• BioNTech
• Daiichi Sankyo Co. Ltd
• Inovio Pharmaceuticals, Inc.
• Moderna
• Johnson & Johnson
• Merck & Co.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd
• Sinovac
• Other prominent players

Market Segmentation Overview:

By Type

• Conjugate Vaccines
• Inactivated Vaccines
• Subunit and Polysaccharide Vaccines
• Live Attenuated Vaccines
• Messenger RNA (mRNA) Vaccines
• Nucleic Acid Vaccines
• Viral Vector Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

By Disease Indication

• Bacterial Diseases
• Viral Diseases

By Route of Administration

• Intramuscular
• Subcutaneous
• Oral Administration
• Intra Venous
• Others

By Patient Group

• Adult
• Pediatric

By End User

• Hospitals
• Clinics
• Vaccination Centers
• Academic & Research Institutes

By Region

• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific